Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI coach for therapists: could a digital tool improve psychosis care?

NCT ID NCT05127837

Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This study tested a new digital tool called CBTpro that uses artificial intelligence to help therapists improve their skills in cognitive behavioral therapy for psychosis (CBTp). Over 600 participants, including therapists and their clients with conditions like schizophrenia or bipolar disorder, took part. The goal was to see if the tool could support high-quality therapy training and delivery in routine care settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CBTpro (a digital tool using artificial intelligence to help therapists practice cognitive behavioral therapy for psychosis)
What this could lead to
If successful, this tool could help more therapists deliver high-quality therapy for psychosis, potentially improving patient outcomes across the U.S.
What could go wrong
This is a development and evaluation study, not a treatment trial. The tool is meant for training therapists, not directly treating patients. Results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

601 people

The number who actually took part.

Started

Jun 2022

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Client Inclusion: Adults who speak English, meet with their provider who is participating in the study at least bi-weekly (2x a month), and do not plan to leave services in the next 6 months. Qualifying diagnoses for clients include: schizophrenia; schizoaffective disorder; schizophreniform disorder; delusional disorder; other specified schizophrenia spectrum and other psychotic disorder; unspecified schizophrenia spectrum or other psychotic disorder; bipolar disorder with psychotic features; major depressive disorder with psychotic features Exclusion criteria: Dx of psychosis secondary to substance intoxication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder delusional disorder depressive disorder major depressive disorder psychotic disorder Psychotic Disorders schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar disorder Depressive disorder Psychosis Schizo affective disorder Schizophrenia

Contacts and locations

Locations

  • Cascadia

    Portland, Oregon, 97207, United States

  • Coleman Health Services

    Akron, Ohio, 44223, United States

  • Community Mental Health Authority of Clinton, Eaton, and Ingham Counties (CEICMH)

    Lansing, Michigan, 48823, United States

  • Comprehensive Healthcare

    Yakima, Washington, 98902, United States

  • Frontier Behavioral Health

    Spokane, Washington, 99208, United States

  • Harborview Medical Center

    Seattle, Washington, 98104, United States

  • Integrated Services of Kalamazoo

    Kalamazoo, Michigan, 49007, United States

  • Lifeworks NW

    Portland, Oregon, 97221, United States

  • PeaceHealth

    Eugene, Oregon, 97401, United States

  • Psynergy

    Morgan Hill, California, 93927, United States

  • Sound Health

    Seattle, Washington, 98122, United States

  • South Central Health and Rehabilitation Programs

    Los Angeles, California, 90003, United States

  • Telecare

    San Jose, California, 95116, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.